FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2795267642> ?p ?o ?g. }

• W2795267642 endingPage "996" @default.
• W2795267642 startingPage "988" @default.
• W2795267642 abstract "To evaluate the impact of intravitreal aflibercept (EYLEA, Regeneron Pharmaceuticals, Tarrytown, NY) versus laser on progression of diabetic retinopathy (DR) severity in Intravitreal Aflibercept Injection in Vision Impairment due to DME (VIVID-DME) and Study of Intravitreal Aflibercept Injection in Patients with Diabetic Macular Edema (VISTA-DME). Secondary and exploratory analyses of 2 phase 3, randomized, controlled studies. All patients with a baseline Diabetic Retinopathy Severity Scale (DRSS) score based on fundus photograph (full analysis), patients who progressed to proliferative DR (PDR) (safety analysis) in VIVID-DME (n = 403) and VISTA-DME (n = 459), or both. We randomized patients with diabetic macular edema (DME) to intravitreal aflibercept 2 mg every 4 weeks (2q4), intravitreal aflibercept 2 mg every 8 weeks after 5 initial monthly doses (2q8), or macular laser photocoagulation at baseline and sham injections at every visit. Proportions of patients with 2-step or more and 3-step or more improvements from baseline in DRSS score, who progressed to PDR, and who underwent panretinal photocoagulation (PRP). Among patients with an assessable baseline DRSS score, most showed moderately severe or severe nonproliferative DR. The proportions of patients treated with 2q4, 2q8, and laser with a 2-step or more improvement in DRSS score at week 100 were 29.3%, 32.6%, and 8.2%, respectively, in VIVID-DME and 37.0%, 37.1%, and 15.6%, respectively, in VISTA-DME; the proportions with a 3-step or more improvement in DRSS score were 7.3%, 2.3%, and 0%, respectively, and 22.7%, 19.9%, and 5.2%, respectively. Fewer patients in the 2q4 and 2q8 groups versus the laser group progressed to PDR at week 100 in VISTA-DME (1.5% and 2.2% vs. 5.3%) and VIVID-DME (3.2% and 2.0% vs. 12.3%). The proportions of patients who underwent PRP were 2.9%, 0.7%, and 4.5%, respectively, in VIVID-DME and 1.9%, 0.7%, and 5.2%, respectively, in VISTA-DME. The most frequent serious ocular adverse event at week 100 was cataract (pooled intravitreal aflibercept, 1.7% of patients; laser, 3.5% of patients). These analyses demonstrate the benefit of intravitreal aflibercept over laser with respect to DR progression, suggesting a benefit on DME, and on underlying DR." @default.
• W2795267642 created "2018-04-06" @default.
• W2795267642 creator A5000484280 @default.
• W2795267642 creator A5013577573 @default.
• W2795267642 creator A5016922490 @default.
• W2795267642 creator A5023056749 @default.
• W2795267642 creator A5023996852 @default.
• W2795267642 creator A5028026239 @default.
• W2795267642 creator A5030449236 @default.
• W2795267642 creator A5034221126 @default.
• W2795267642 creator A5038795358 @default.
• W2795267642 creator A5058044536 @default.
• W2795267642 creator A5061673504 @default.
• W2795267642 creator A5065670758 @default.
• W2795267642 creator A5072551893 @default.
• W2795267642 creator A5076161106 @default.
• W2795267642 creator A5080631815 @default.
• W2795267642 date "2018-10-01" @default.
• W2795267642 modified "2023-10-14" @default.
• W2795267642 title "Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies" @default.
• W2795267642 cites W1786299986 @default.
• W2795267642 cites W1977644809 @default.
• W2795267642 cites W1999957425 @default.
• W2795267642 cites W2050020278 @default.
• W2795267642 cites W2057789225 @default.
• W2795267642 cites W2078089300 @default.
• W2795267642 cites W2102463203 @default.
• W2795267642 cites W2111693183 @default.
• W2795267642 cites W2138480916 @default.
• W2795267642 cites W2171946822 @default.
• W2795267642 cites W2178156144 @default.
• W2795267642 cites W2188846692 @default.
• W2795267642 cites W2289200040 @default.
• W2795267642 cites W2322256252 @default.
• W2795267642 cites W2337454357 @default.
• W2795267642 cites W2528599938 @default.
• W2795267642 cites W2607606893 @default.
• W2795267642 cites W2610772121 @default.
• W2795267642 cites W2616361514 @default.
• W2795267642 cites W2769264260 @default.
• W2795267642 cites W4214688168 @default.
• W2795267642 cites W4244248663 @default.
• W2795267642 cites W922383587 @default.
• W2795267642 doi "https://doi.org/10.1016/j.oret.2018.02.011" @default.
• W2795267642 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31047501" @default.
• W2795267642 hasPublicationYear "2018" @default.
• W2795267642 type Work @default.
• W2795267642 sameAs 2795267642 @default.
• W2795267642 citedByCount "46" @default.
• W2795267642 countsByYear W27952676422018 @default.
• W2795267642 countsByYear W27952676422019 @default.
• W2795267642 countsByYear W27952676422020 @default.
• W2795267642 countsByYear W27952676422021 @default.
• W2795267642 countsByYear W27952676422022 @default.
• W2795267642 countsByYear W27952676422023 @default.
• W2795267642 crossrefType "journal-article" @default.
• W2795267642 hasAuthorship W2795267642A5000484280 @default.
• W2795267642 hasAuthorship W2795267642A5013577573 @default.
• W2795267642 hasAuthorship W2795267642A5016922490 @default.
• W2795267642 hasAuthorship W2795267642A5023056749 @default.
• W2795267642 hasAuthorship W2795267642A5023996852 @default.
• W2795267642 hasAuthorship W2795267642A5028026239 @default.
• W2795267642 hasAuthorship W2795267642A5030449236 @default.
• W2795267642 hasAuthorship W2795267642A5034221126 @default.
• W2795267642 hasAuthorship W2795267642A5038795358 @default.
• W2795267642 hasAuthorship W2795267642A5058044536 @default.
• W2795267642 hasAuthorship W2795267642A5061673504 @default.
• W2795267642 hasAuthorship W2795267642A5065670758 @default.
• W2795267642 hasAuthorship W2795267642A5072551893 @default.
• W2795267642 hasAuthorship W2795267642A5076161106 @default.
• W2795267642 hasAuthorship W2795267642A5080631815 @default.
• W2795267642 hasBestOaLocation W27952676421 @default.
• W2795267642 hasConcept C118487528 @default.
• W2795267642 hasConcept C126322002 @default.
• W2795267642 hasConcept C134018914 @default.
• W2795267642 hasConcept C2776694085 @default.
• W2795267642 hasConcept C2777802072 @default.
• W2795267642 hasConcept C2778257484 @default.
• W2795267642 hasConcept C2778749236 @default.
• W2795267642 hasConcept C2779829184 @default.
• W2795267642 hasConcept C2780347916 @default.
• W2795267642 hasConcept C2985127711 @default.
• W2795267642 hasConcept C555293320 @default.
• W2795267642 hasConcept C71924100 @default.
• W2795267642 hasConceptScore W2795267642C118487528 @default.
• W2795267642 hasConceptScore W2795267642C126322002 @default.
• W2795267642 hasConceptScore W2795267642C134018914 @default.
• W2795267642 hasConceptScore W2795267642C2776694085 @default.
• W2795267642 hasConceptScore W2795267642C2777802072 @default.
• W2795267642 hasConceptScore W2795267642C2778257484 @default.
• W2795267642 hasConceptScore W2795267642C2778749236 @default.
• W2795267642 hasConceptScore W2795267642C2779829184 @default.
• W2795267642 hasConceptScore W2795267642C2780347916 @default.
• W2795267642 hasConceptScore W2795267642C2985127711 @default.
• W2795267642 hasConceptScore W2795267642C555293320 @default.
• W2795267642 hasConceptScore W2795267642C71924100 @default.
• W2795267642 hasIssue "10" @default.
• W2795267642 hasLocation W27952676421 @default.

• next